NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company focused on antiviral drug development, has announced that its Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo Ebolavirus and other Ebola viruses is expected to commence soon in the Democratic Republic of Congo (DRC). The company has received regulatory approval from the local agency ACOREP and has appointed Professor Patrick Katoto as principal investigator. Preparatory activities, including staff training, are underway, and the NV-387 drug product is already available in the DRC, with first patient dosing anticipated within a few weeks, barring any outbreak-related impediments.
The significance of this trial lies in the potential advantages of an oral antiviral treatment in resource-limited outbreak settings. Unlike treatments that require intravenous infusions, an oral formulation can be administered more easily, reducing the burden on healthcare infrastructure and improving patient access. NV-387 is designed as a broad-spectrum antiviral that mimics host-side features required by viruses for infection, potentially offering a novel mechanism of action.
Om Sai Clinical Research Private Limited is serving as the contract research organization (CRO) for the Phase II trial, as well as for the company's planned Phase II trial of NV-387 Oral Gummies for the treatment of Mpox in the DRC. This parallel development underscores the potential versatility of NV-387 against multiple viral threats.
NanoViricides' lead drug candidate, NV-387, is being developed for a range of viral infections, including respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. The company's approach is based on its nanoviricide technology, which utilizes specially designed nanomaterials to target and dismantle viruses.
The Ebola outbreak in the DRC, caused by the Bundibugyo strain, poses a significant public health challenge. An effective oral treatment could be a critical tool in controlling outbreaks and reducing mortality. The trial's initiation follows regulatory approval and local collaboration, which are essential for conducting clinical research in the region.
NanoViricides has a broad pipeline, including NV-HHV-1 for shingles and NV-CoV-2 for COVID-19. The company's business model involves licensing technology from TheraCour Pharma, Inc., and it holds exclusive licenses for several viral targets. The path to drug approval is lengthy and capital-intensive, but the potential impact of a successful oral antiviral for Ebola could be substantial.
As the trial progresses, the company will need to demonstrate both safety and efficacy in humans. While preclinical and early-stage data have been promising, there is no guarantee of success. However, the advancement to Phase II in an outbreak setting is a critical step toward addressing a significant unmet medical need.
Investors and public health officials will be watching closely as NanoViricides moves forward with this trial. The outcome could have implications not only for Ebola treatment but also for the broader application of oral antiviral therapies in emerging viral outbreaks.
For more information on NanoViricides and its pipeline, visit the company's newsroom at https://ibn.fm/NNVC.
